Shenzhen Edge Medical (2675) H1 2025 earnings summary

Executive summary

• Audited consolidated financials cover years ended Dec 31, 2023 and 2024, and six months ended June 30, 2025, prepared for an IPO prospectus.

• The group designs, develops, manufactures, and sells surgical robots, with all subsidiaries 100% owned.

• Financials prepared under IFRS for the first time, with transition date Jan 1, 2023.

Financial highlights

• Revenue: RMB 48.0M (2023), RMB 160.0M (2024), RMB 149.4M (H1 2025).

• Net loss: RMB 212.9M (2023), RMB 218.5M (2024), RMB 89.1M (H1 2025).

• Gross profit: RMB 28.5M (2023), RMB 98.1M (2024), RMB 93.9M (H1 2025).

• R&D expenses: RMB 171.2M (2023), RMB 226.2M (2024), RMB 96.5M (H1 2025).

• Basic and diluted loss per share: RMB (0.59) (2023), RMB (0.61) (2024), RMB (0.25) (H1 2025).

Outlook and guidance

• RMB 20.6M in future revenue expected from existing contracts as of June 30, 2025, to be recognized over the next 10 years.

• No dividends declared or paid during the period.